Wait S H
Bull Cancer. 1996 Sep;83(9):769-72.
The adoption in France of a national breast cancer screening policy will depend in part on economic factors. These include the investments and costs of screening and the cost-effectiveness of screening as compared to other health interventions. There exist few economic data on breast cancer screening in France. Existing studies have estimated the cost of screening at 374 FF per woman screened, however they provide no indication of the cost-effectiveness of screening. The application of cost-effectiveness ratios obtained in other countries is difficult given the strong presence of spontaneous screening which is unique in France. Spontaneous screening may undermine the marginal gain in life expectancy expected from organized screening, however it does not offer the quality of organized screening in terms of systematic double reading and quality assurance of mammographic units. Precise and reliable data on the costs and effectiveness associated with both these forms of screening must be collected before reaching any conclusions on cost-effectiveness. These data will allow for the development of a coherent and equitable policy on screening in France which is justified both in economic terms and in terms of public health.
法国全国性乳腺癌筛查政策的采用部分取决于经济因素。这些因素包括筛查的投资和成本，以及与其他健康干预措施相比筛查的成本效益。法国关于乳腺癌筛查的经济数据很少。现有研究估计每位接受筛查的女性的筛查成本为374法郎，然而这些研究并未表明筛查的成本效益。鉴于法国自发筛查的盛行，应用在其他国家获得的成本效益比很困难。自发筛查可能会削弱有组织筛查预期的预期寿命边际收益，然而在乳腺钼靶单位的系统双人阅片和质量保证方面，它无法提供有组织筛查的质量。在得出任何关于成本效益的结论之前，必须收集与这两种筛查形式相关的成本和效益的精确可靠数据。这些数据将有助于制定一项在经济和公共卫生方面都合理的法国筛查连贯且公平的政策。
